Bausch Health (BHC)
(Delayed Data from NYSE)
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.71 USD
+0.09 (1.04%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth D Momentum A VGM
Zacks News
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bausch Health (BHC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Bausch Health (BHC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.
Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up
by Zacks Equity Research
Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Sell Stocks for December 9th
by Zacks Equity Research
ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.
Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered
by Zacks Equity Research
Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.
Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Bausch (BHC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.
Why Is Bausch (BHC) Up 23% Since Last Earnings Report?
by Zacks Equity Research
Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
by Zacks Equity Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
by Zacks Equity Research
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
by Zacks Equity Research
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Bausch Health (BHC) Q2 Earnings?
by Zacks Equity Research
An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.